Continued revenue erosion by generics, a slowdown at the FDA, and “over-built” infrastructure make for a continuation of an inorganic growth strategy for many pharmaceutical firms.  On the plus side, vaccine use is booming, there’s a full pipeline of new drugs and new markets, and companies are beginning to outsource and standardize infrastructure.
 
Key performance indicators (KPIs) in sales operations, for example, include channel efficiency, time to market, field force effectiveness, and new rep training.

See what initiatives can be started using the xPM Cycle from Business Foundation
IndustryVerticalTearsPharma
PharmaDashboard

Some typical extended performance management initiatives include R&D spend models, Revenue forecasts by product and channel, Sales and Marketing Intelligence (dashboards), operational excellence scorecards, and product profitability analysis.
 
“…we are working on 25 launches over the next three years, some of them will be delayed that probably wouldn't have been delayed if we had those 25 products even two years ago. But such is life.”
J. P. Garnier, GlaxoSmithKline CEO (Q3, 2007 Earnings call).

BROADSHEET SNEAK-PEEK: PHARMACEUTICAL

POTENTIAL INITIATIVES THAT CAN BE STARTED FROM THE DISCOVERY ANALYSIS

PEER BENCHMARKS: PHARMACEUTICAL PERFORMANCE MARKERS

You need to upgrade your Flash Player or to allow javascript to enable Website menu.
Get Flash Player

Delivering the

SiteMapIcon
Privacy Policy Terms of Use